The Lamming laboratory’s goal is to understand how nutrient-responsive signaling pathways can be harnessed to promote health and longevity.
Assay and biomarker development
Drug development for solid tumors
Chromatin Dynamics in Development and Cancer
Dr. Douglas McNeel, MD PhD is a genitourinary medical oncologist with a translational laboratory research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, evaluating DNA vaccines in murine models to elicit tumor-reactive CD8+ T cells, and translating these studies to human clinical trials.
Immunomodulation of the tumor microenvironment with radiation therapy; novel approaches to in situ cancer vaccination
Extracellular matrix; cell adhesion
The overall goal of my laboratory and translational research is the development of targeted therapies and immunotherapies to improve patient survival while reducing short- and long-term side effects from largely untargeted conventional chemotherapies. Currently, my laboratory focuses on three major areas in targeted cancer therapies.
Cell-matrix signaling in the human eye; glaucoma